Home/Filings/4/0001626533-18-000002
4//SEC Filing

ARNETT JEAN M 4

Accession 0001626533-18-000002

CIK 0001493712other

Filed

Aug 23, 8:00 PM ET

Accepted

Aug 24, 2:29 PM ET

Size

14.8 KB

Accession

0001626533-18-000002

Insider Transaction Report

Form 4
Period: 2016-09-26
ARNETT JEAN M
DirectorVP, Corporate Strategy10% Owner
Transactions
  • Other

    Stock Options (Right to Buy)

    2016-09-261,250,0000 total
    Exercise: $0.05Common Stock (1,250,000 underlying)
  • Other

    Stock Options (Right to Buy)

    2016-09-261,250,0000 total
    Exercise: $0.05Common Stock (1,250,000 underlying)
  • Other

    Stock Options (Right to Buy)

    2016-09-261,250,0000 total
    Exercise: $0.05Common Stock (1,250,000 underlying)
  • Other

    Stock Options (Right to Buy)

    2016-09-262,500,0000 total
    Exercise: $0.05Common Stock (2,500,000 underlying)
  • Other

    Stock Options (Right to Buy)

    2016-09-262,500,0000 total
    Exercise: $0.05Common Stock (2,500,000 underlying)
Footnotes (6)
  • [F1]The Options were to vest upon the completion of first clinical trial and delivery of final white paper for the first clinical trial.
  • [F2]The Options were to vest upon the design and commencement of the second clinical trial.
  • [F3]The Options were to vest upon the completion of second clinical trial and delivery of final white paper for the second clinical trial.
  • [F4]The Options were to vest upon the design and commencement of the third clinical trial.
  • [F5]The Options were to vest upon the completion of the third clinical trial and delivery of final white paper for the third clinical trial.
  • [F6]Options that would have vested were to expire 5 years after vesting. Options that have not vested would have expired on 12/31/2019.

Issuer

Cell MedX Corp.

CIK 0001493712

Entity typeother

Related Parties

1
  • filerCIK 0001626660

Filing Metadata

Form type
4
Filed
Aug 23, 8:00 PM ET
Accepted
Aug 24, 2:29 PM ET
Size
14.8 KB